Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (https://pubmed.ncbi.nlm.nih.gov/35603936/). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations.

 

 

Download entire guideline document in the 2023 version: 

Last updated
Changes
Download
Introduction, scoping, population and targeted users
09/2023
Editorial changes
Disease severity and treatment goals
09/2023
No changes
Methods and evidence section
09/2023
Editorial changes
Main Recommendations and Decision Grid
09/2023
Deucravacitinib was added
Implementation slides
01/2024
New data added
IFPA Guideline
09/2023
Editorial changes

Last updated
Changes
Download
Acitretin
03/2023
No changes
Ciclosporin
03/2023
Reference added
Fumarates
03/2023
No changes
Methotrexate
03/2023
New data added
Adalimumab
03/2023
No changes
Apremilast
03/2023
New data added
Bimekizumab
09/2023
New data added
Brodalumab
09/2023
New data added
Certolizumab – Pegol
09/2023
No changes
Deucravacitinib
09/2023
New chapter
Etanercept
03/2023
No changes
Guselkumab
03/2023
No changes
Infliximab
03/2023
No changes
Ixekizumab
09/2023
New data added
Risankizumab
09/2023
New data added
Secukinumab
09/2023
New data added
Tildrakizumab
03/2023
No changes
Ustekinumab
03/2023
No changes
Biosimilars
09/2023
New data added
Newly approved medications and treatments in the pipeline
10/2021
No changes

Last updated
Changes
Download
Psoriatic arthritis
03/2023
New data added, recommendations changed
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Cancer
09/2023
New data added
Depression
09/2023
New data added
Diabetes Mellitus
09/2023
New data added, recommendations changed
Heart disease
03/2023
New data added
Kidney disease
03/2023
New data added
Neurological diseases
09/2023
New data added
Viral Hepatitis
01/2024
Chapter currently under review
Tuberculosis: Screening
09/2023
Editorial changes
Tuberculosis: Treatment
09/2023
Editorial changes
Wish for child / Pregnancy
10/2021
Time until pregnancy added for bimekizumab
Vaccinations
03/2023
Completely new written
Inmunogenicity
10/2021
No changes

Last updated
Changes
Download
Methods Report
09/2023
Editorial changes
Strength and limitations
09/2023
No changes
Abbreviations
09/2023
Editorial changes